Professors Brian Lipworth, Zuzana Diamant, and Philippe Gevaert delve into the complexities of managing patients with both severe and/or uncontrolled CRSwNP and co-existing asthma through an evaluation of the diagnostic challenges, personalized treatment strategies, and the latest advancements in understanding the interconnected pathophysiology of these type 2 airway diseases.

Embark on this interactive triathlon challenge to uncover the interplay of type 2 inflammation, barrier dysfunction, and neuroimmune dysregulation in the disease pathology of CRSwNP.

Join Profs. Sachio Takeno and Joaquim Mullol for an educational symposium highlighting the multifaceted burden associated with loss of smell and congestion in patients with uncontrolled CRSwNP.
Join the effort to improve CRSwNP care. World Anosmia Day serves as an opportunity to raise awareness about the loss of the sense of smell. Access some of countless educational resources with ADVENT below.

Learn how loss of smell in CRSwNP is a key symptom for both patients and providers.

Dr. Backer discusses assessing remission in CRSwNP by evaluating the patient's sense of smell in this video clip from the EAACI 2024 symposium.

Prof. Peter Hellings discusses the interconnection between the pathophysiology, burden and clinical management of uncontrolled and/or severe CRSwNP

This video clip from the EAACI 2024 symposium discusses whether patients with CRSwNP should undergo a surgery.

In this video clip from the EAACI 2024 symposium, Dr. Mullol discusses the challenge of defining active nasal disease using an endoscope.

In this video soundbite from the EAACI 2025 symposium, Dr. Brian Lipworth discusses that co-existing type 2 inflammatory diseases are common in patients with CRSwNP & increasing severity of asthma is associated with higher severity of CRS and prevalence of nasal polyps. Additionally, he explains that patient burden is substantially greater when asthma and CRSwNP are co-existing.

In this video soundbite from the EAACI 2025 symposium, Dr. Zuzana Diamant explains pathophysiological mechanisms underlying asthma and CRSwNP, and how type 2 inflammatory cytokines drive airway remodelling in patients with severe asthma. Additionally, patients with co-existing asthma and CRSwNP have a higher type 2 inflammatory burden than patients with asthma alone.

Dr. Stella Lee and Profs. Peter Hellings and Wytske Fokkens discuss type 2 inflammation, partnering with patients to improve outcomes, and real-world data on biologic effectiveness in CRSwNP.